Literature DB >> 35900168

Encouraging Rigorous Patient-Generated Data All Along the Drug Development Continuum.

Vishal Bhatnagar1, Paul G Kluetz1.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 35900168      PMCID： PMC9552273          DOI： 10.1093/jnci/djac129

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   11.816


× No keyword cloud information.
  8 in total

1.  Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials: Symptomatic Adverse Events, Physical Function, and Disease-Related Symptoms.

Authors:  Paul G Kluetz; Ashley Slagle; Elektra J Papadopoulos; Laura Lee Johnson; Martha Donoghue; Virginia E Kwitkowski; Wen-Hung Chen; Rajeshwari Sridhara; Ann T Farrell; Patricia Keegan; Geoffrey Kim; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2016-01-12       Impact factor: 12.531

2.  FDA review summary of patient-reported outcome results for ibrutinib in the treatment of chronic graft versus host disease.

Authors:  Bellinda L King-Kallimanis; Tanya Wroblewski; Virginia Kwitkowski; R Angelo De Claro; Thomas Gwise; Vishal Bhatnagar; Ann T Farrell; Paul G Kluetz
Journal:  Qual Life Res       Date:  2020-02-25       Impact factor: 4.147

3.  The Wild West of Checkpoint Inhibitor Development.

Authors:  Julia A Beaver; Richard Pazdur
Journal:  N Engl J Med       Date:  2021-12-15       Impact factor: 91.245

4.  FDA Approval Summary: Belumosudil for Adult and Pediatric Patients 12 Years and Older with Chronic GvHD after Two or More Prior Lines of Systemic Therapy.

Authors:  Donna Przepiorka; Robert Q Le; Alexei Ionan; Ruo-Jing Li; Ying-Hong Wang; Ramadevi Gudi; Soumya Mitra; Jonathon Vallejo; Olanrewaju O Okusanya; Lian Ma; Yuching Yang; Paresma Patel; Djelila Mezaache; Rakhi Shah; Anamitro Banerjee; Sherita McLamore; Adam N Maung; Kirsten B Goldberg; Richard Pazdur; Marc R Theoret; R Angelo De Claro
Journal:  Clin Cancer Res       Date:  2022-06-13       Impact factor: 13.801

Review 5.  U.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in Review.

Authors:  Shaily Arora; Preeti Narayan; Gwynn Ison; Tara Berman; Daniel L Suzman; Suparna Wedam; Tatiana M Prowell; Soma Ghosh; Reena Philip; Christy L Osgood; Jennifer J Gao; Mirat Shah; Danielle Krol; Sakar Wahby; Melanie Royce; Christina Brus; Erik W Bloomquist; Mallorie H Fiero; Shenghui Tang; Richard Pazdur; Amna Ibrahim; Laleh Amiri-Kordestani; Julia A Beaver
Journal:  Clin Cancer Res       Date:  2022-03-15       Impact factor: 13.801

6.  Approvals in 2021: dangling Accelerated Approvals, drug dosing, new approvals and beyond.

Authors:  Steven Lemery; Richard Pazdur
Journal:  Nat Rev Clin Oncol       Date:  2022-04       Impact factor: 66.675

7.  Listening to the Patient Voice Adds Value to Cancer Clinical Trials.

Authors:  Michael D Brundage; Norah L Crossnohere; Jennifer O'Donnell; Samantha Cruz Rivera; Roger Wilson; Albert W Wu; David Moher; Derek Kyte; Bryce B Reeve; Alexandra Gilbert; Ronald C Chen; Melanie J Calvert; Claire Snyder
Journal:  J Natl Cancer Inst       Date:  2022-10-06       Impact factor: 11.816
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.